Sources allege Russia stole Oxford’s COVID-19 vaccine blueprint to make Sputnik V

Coronavirus Vaccine

Coronavirus Vaccine

Source reveals Russia stole Oxford's COVID-19 vaccine blueprint to make Sputnik V

Sources reveal that Russian spies acquired the COVID-19 vaccine blueprint from Oxford/AstraZeneca shot to make the Sputnik V. Here’s the full scoop on how Russia tried to win the race of producing the world’s first effective COVID-19 vaccine.

How did Russia get hold of the COVID-19 vaccine blueprint?

Security experts revealed to the UK ministers proof that the Kremlin agents stole the COVID-19 vaccine blueprint and plan to make the Sputnik V. As per reports from The Sun, crucial documents and blueprints were stolen by a foreign spy. However, Damia Hinds, the UK Minister for Security declined to comment on the claims. But, he claimed that cyber-assaults were becoming very sophisticated.

As per the sources, a Russian spy in the UK physically got hold of the secret vaccine design. However, it is not clear if the material was a paper in the pharma lab or a vial of the final product. Additionally, MI5 agents previously stated that hackers from Russia launched several strikes on Oxford University. Moreover, the strikes were around the same time that the British researchers announced that they were researching a COVID-19 vaccine.

Is there proof to support the claim?

The Oxford-Astera Zenecateam announced the beginning of the first trial in April 2020. One month later, Moscow announced the invention of their vaccine. Additionally, in August Russian President Vladimir Putin declared on TV that Russia won the global vaccine race by developing the first COVID-19 shot.

While it may seem like a coincidence, it is not. The Sputnik V operates very similarly to the Oxford-Astera Zeneca vaccine. Firstly, they are both viral vector vaccines. Hence, they take the aid of a latent virus for transplanting the immune agent. Additionally, investigation reports reveal that the Russian spies may have taken the vaccine blueprint during the UK’s initial trials.

Exit mobile version